Trade Mind

[Trade Mind @OndStockMind]

#StockMarket
#Trading
#Investing
#WallStreet
#Markets
#Finance
#Stocks
#DayTrading
#SwingTrading
#TechnicalAnalysis
#PriceAction
#Charting
#Traders
#MarketAnalysis

[Trade Mind @OndStockMind]

#Japanesecandles #TraderLife #TradeToEarn

[Trade Mind @OndStockMind]

$IXHL -

About Murray B. Stein

He is one of the world's leading and most influential professionals in the field of psychiatry and public health, with a strong emphasis on anxiety, trauma, and PTSD.

Who is he and what are his roles?

Distinguished Professor of Psychiatry at the UCSD School of Medicine – a particularly high academic rank given to researchers with exceptional contributions.

Professor of Public Health at the Herbert Wertheim School of Public Health and Longevity – combining clinical medicine with epidemiology and influencing health policy.

Senior Psychiatrist at the Veterans Affairs (VA) Health System in San Diego – clinical work with complex populations, including trauma survivors.

Key areas of expertise

Anxiety disorders (especially social anxiety)

PTSD and trauma-related disorders

Psychiatric epidemiology (how and how many mental illnesses appear in the population)

Neurobiology of anxiety

Advanced pharmacological and psychological treatments

Exceptional scientific achievements

800+ peer-reviewed scientific publications – an exceptional figure even by high academic standards.

Continuous federal research funding for over 29 years – indicates continued trust from US health authorities (NIH, federal agencies).

Member of key committees:

FDA Psychopharmacological Drugs Committee – direct influence on the approval of psychiatric drugs.

DSM-5 Working Group for Anxiety Disorders, OCD, and Trauma – i.e., was a co-designer of the official definitions of psychiatric diagnoses.

Editorial Roles and Influence

Holds senior editorial positions in leading psychiatric journals – positioning him as a “gatekeeper” of research quality in the field.

[Trade Mind @OndStockMind]

$IXHL

The text reviews the development of IHL-42X, an experimental drug from Incannex Healthcare intended for the treatment of obstructive sleep apnea (OSA) by oral administration. The drug combines two existing drugs, dronabinol and acetazolamide, which work together to stabilize breathing patterns during the night. The findings of the second phase of the RePOSA trial indicated a significant decrease in respiratory arrest indices and an improvement in the quality of life of patients without serious side effects. The company is now advancing the third phase of the clinical trial in the United States under the supervision of the FDA to confirm the effectiveness of the treatment over time. If approved, the drug could be a breakthrough alternative for patients who have difficulty adapting to traditional CPAP devices. The authors emphasize that this development reflects a broader trend of drug solutions that expand the treatment options for chronic sleep disorders.

https://t.co/QETOw7ewVZ

[Trade Mind @OndStockMind]

$IXHL -

Today will be crucial whether we go back up or down below the six-month low - for me 0.3 is the point of no return.

[Trade Mind @OndStockMind]

@WarrenM17899954 No, I don't have a green holding. Because I didn't go out at the peak. I went out at 0.5 - I went in at 0.6 - unfortunately I'm losing money right now. But with a lot of hope

[Trade Mind @OndStockMind]

$IXHL -

No I don't. I've been in this stock since 05/25 - but I can tell you that I follow it and analyze it quite a bit. The trend looks very bad, but that's the price of a penny stock. If we succeed we will do it big. If not, we have lost quite a bit.

[Trade Mind @OndStockMind]

$IXHL -

The text presents an in-depth interview with Joel Latham, CEO of the biopharmaceutical company Incannex Healthcare, focusing on the principles of strong leadership and crisis management. Latham reviews the company's developments in the field of combination drugs, emphasizing clinical successes in the treatment of sleep apnea and anxiety. Throughout the conversation, he explains how advance strategic planning and maintaining transparency with stakeholders enable an organization to navigate periods of economic uncertainty. In addition, the manager shares insights on building independent teams and cultivating an organizational culture based on flexibility and problem-solving. In conclusion, the source emphasizes that financial discipline and composure are the key keys to turning challenges into opportunities for long-term growth.

https://t.co/OCLSsQeCdy

[Trade Mind @OndStockMind]

$IXHL -

In life, you can choose to see yourself as a loser, as a "sucker" who lost in the capital market.
And you can choose to see the full picture.

First, I wish only good things — to bears and bulls alike.
But when we honestly examine our insistence on staying in this stock, one thing becomes clear and clear:
In terms of the quality of the company and its clinical progress — we were not wrong. On the contrary. We won hugely.

We did not act blindly, and we were not pushed into a corner with no way out.
We were the ones who stayed here in cold blood.
We stood the test of time, in pain, by not taking profits, and in periods when it was much easier to give up.

And today — we can hold our heads up high and say with a clear voice: we were right.

We were right — when they said that the results of Phase 2 would be disappointing.

We were right — when they said that the stock would not receive another extension.

We were right — when they said that a fast track would not be approved.
And we were right — when the company won recognition, a decorated award, and significant honor in the field in which it operates.

I will stay here until the end.
And even if I lose — I will know one thing:
I did not lose out of fear. I did not give up out of weakness.
If I lose — I will lose with honor.

[Trade Mind @OndStockMind]

Different trading strategies require a dedicated computer configuration, tailored to the unique needs of each strategy. However, a common feature of most traders' work configurations is their respective use.

This configuration allows for convenient display of essential information - real-time price quotes, technical charts, indicators, market depth and news - thus contributing to the ability to make quick and accurate decisions in a dynamic environment.

[Trade Mind @OndStockMind]

Trading Booklet · Introduction
This book is designed to provide the reader with a systematic and in-depth educational framework for understanding the principles of technical analysis and their application in trading in the financial markets. Its goal is not to teach a single tool or a "winning" strategy, but to develop a broad and systematic understanding of market behavior, price movement, and the way in which trading decisions are made over time.
The book is structured as a gradual learning process, in which each chapter builds on the foundations built before it. "Technical analysis" is not a collection of disconnected techniques, but a complete and consistent language. To understand this language in depth, it is recommended to study the material in order and avoid skipping parts. Only a connection between all the components allows for a complete, well-founded, and consistent view of the market.
The booklet is divided into three main parts:
1) The first part deals with the basics of technical analysis, and includes an introduction to Japanese candlesticks, trends, market structures, support and resistance levels, and especially the principles of risk management - the cornerstone of any professional trading activity.
2) The second part is dedicated to trading tools and strategies, including "Fibonacci", Gann, and reversal zones. The emphasis in this part is not on searching for specific solutions, but on the systematic, consistent and well-founded application of the tools as part of an organized work process.
3) The third part deals with indicators, which are presented as an aid to understanding the market's reaction and not as a forecasting tool. In each indicator chapter, definition tables and buy and sell signal tables are integrated, allowing for systematic work, rapid repetition and practical application of the material learned.
The main value of the booklet is not in the number of tools taught, but in the development of correct commercial thinking. At the end of the reading, the reader should know how to read the market, how to filter out noise, how to cross-reference different tools, and how to make decisions within a clear framework of risk management and a structured work process.
Working with the booklet is recommended as active work. For each tool, strategy, or indicator studied, it is recommended to simultaneously open a chart on a different trading platform, including: TradingView - IBKR - and examine the actual tool on the chart. Combining reading with direct observation of the practical application significantly deepens understanding.
The booklet is intended to be used as both a learning tool and a working tool. It does not replace experience or judgment, but rather provides a supporting framework that enables responsible, balanced, and ongoing trading.
Understanding the language of price, combined with judgment and common sense, reduces uncertainty and turns trading from a process of guesswork into a process of conscious and informed decision-making.

[Trade Mind @OndStockMind]

$IXHL -

It's explicitly stated in the K8 report - they raised an additional $12 million - apparently through an ATM. And since the report was published, I estimate they've raised another $3 million. That's about $15 million.

Financial Position and Capital Discipline

●Reported cash and cash equivalents exceeding $70 million, providing operating runway well into 2027

●Completed a $12.5 million private placement financing
●Eliminated all outstanding Series A warrants, removing legacy dilution overhang

●Authorized a $20 million share repurchase program
●Maintained disciplined and limited use of its at-the-market (ATM) facility

[Jarin Sawanboonchun @sawanboonc38855]

@OndStockMind Where do you get 85 millions. They have only 70 million recently

[Trade Mind @OndStockMind]

$IXHL

You can check out these experts - and how serious this company is. It's true that we are disappointed with the share price, but once it breaks out - there will be no stopping it.

[Trade Mind @OndStockMind]

$IXHL -

The text reviews Incannex Healthcare's winning of a prestigious research and development award for the development of an innovative drug for the treatment of sleep apnea. The company is developing IHL-42X, a drug combination that is taken by swallowing and is intended to replace the invasive mechanical devices that are currently used as the standard of care. The findings of the second phase of clinical trials showed a significant decrease in respiratory arrest events and a significant improvement in the quality of life of patients. The company is now preparing for advanced trials to compare the effectiveness of the combination against its individual components and placebo drugs. This scientific approach marks a potential breakthrough in providing a solution for patients who do not adapt to existing treatments. The results of the study emphasize the importance of pharmacological innovation in the treatment of chronic respiratory diseases.

https://t.co/Tnbxbo9bB4

[Trade Mind @OndStockMind]

$IXHL -

https://t.co/y3dWJR2fQm

On January 22, 2026, Incannex Healthcare Inc. Announces Formation of Clinical Advisory Board for PSX-001 Program. Further information is included in the press release attached as Exhibit 99.1 hereto, which is incorporated by reference into this Item 8.01.

The real importance of the announcement (in brief)

This is an announcement that signals:

PSX-001 has moved from an internal experimental phase to a serious regulatory planning phase

This is not a peak point – it is a transition point.

1. This is a phase change in development (and not just “another update”)

Companies do not establish a Clinical Advisory Board:

If they do not intend to enter a significant clinical trial

If they do not have internal data that encourages continuation

If there is no regulatory horizon

📌 CAB is established at exactly the stage when:

Endpoints need to be chosen

A trial design needs to be decided

A line needs to be drawn up with the FDA

That is to say:

PSX-001 is no longer an “idea” – it is entering the execution track.

2. The composition of the CAB = a strong message to the market and the FDA

The company chose:

The most important names in psychiatry

Experts in GAD, mood disorders, anxiety

These are people who:

Know the FDA personally

Have sat on committees

Know what goes up and what falls down

📌 This is a clear message:

“We are not going to gamble on a trial. We are coming prepared.”

3. This is not aimed at retail – this is aimed at institutional investors

Most small investors:

Not excited

Don't understand the meaning

But:

Analysts

Biotech funds

FDA-savvy investors

Yes, they do.

This is a message of:

Building trust

Reducing perceived risk

Creating a continuum for future value inflection

4. Why was this announced now – and not later

Timing = hint:

The company:

After a year with clinical progress

With strong cash

With regulatory experience from IHL-42X

📌 Now is the time to “expand the story”:

Not just OSA

But also GAD

Not one drug → clinical platform

5. What does this mean in practice going forward

Not tomorrow, but logically:

We can expect

An announcement on pre-IND / IND

Trial details (design, population, endpoints)

Schedules

And maybe – later – a partner or dedicated funding

This is a milestone that precedes these announcements.

Bottom line (most important)

If I translate the announcement into the language of the capital market:

“PSX-001 has moved from research to clinical with real intent to reach the market.”

Not:

Hype

Not pump

Not news that immediately increases the price

But:

Building value

Reducing future risk

Preparing the ground for significant events

[Trade Mind @OndStockMind]

$IXHL -

*Share – IXHL*
Situation Analysis:
Market Value: $125 Million
Company Cash: $85 Million
*Share Price: 0.3583*
.
*After extensive review in forums and conversation with people who understand, this is a stock that is "unnaturally" undervalued by the norm*.
.
2025 – 2026:
*Clinical success at the highest levels*.
2 clinical trials of an oral drug for obstructive sleep apnea, with the best data ever presented. Won the *R&D award in the Respiratory Disorders category of the 2025 Clinical Trials Excellence Awards* for its work in advancing IHL-42X, the company's fixed-dose oral combination product for the treatment of obstructive sleep apnea (OSA).. FDA (Food and Drug Administration) fast track approval.
2 highly successful clinical trials for a drug for anxiety and PTSD.
.
Where is the problem and concern?: Currently, Incannex Healthcare (IXHL) stock *is required to comply with Nasdaq’s compliance requirements until the end of the extension period granted to it following failure to comply with the minimum price rule*. What does this mean in practice? Nasdaq requires a closing price above $1 for at least 10 consecutive trading days within the time window granted in the extension
.
The deadline for compliance with the minimum price requirement (Bid Price Rule) is April 20, 2026. *Nasdaq granted IXHL a 180-day extension from October 22, 2025 to achieve a closing price of at least $1.00 per share for 10 consecutive trading days within the extension period*.
.
*What this means in practice*: If by April 20, 2026, IXHL does not meet the minimum price requirement of $1.00 per share for at least 10 consecutive trading days (or an extended compliance period at Nasdaq's discretion), Nasdaq may initiate a process to remove the stock from the list (delisting).
.
*Investor Strategy*: Shares held by the public: 342 million shares. This is a very large float. In order to reach a price of a dollar or more, this means that the company's value must be $342 million. In other words, an additional $220 million will be added to the company's market value. Right now, this is not happening with all the great announcements made by the company.
.
Therefore, if there is no announcement and announcement of cooperation and a huge investment in this company, there will be no escape from a reverse split.
.
Compliance Deadline: April 20, 2026 - Notification Required: At least 5 business days in advance of the 8-K requirement + Nasdaq notification (cannot be bypassed).
.
*Realistic Timeline – Step by Step*:

🔹 Step 1: Now → End of February 2026 - Relatively Safe Zone
The company is still within a comfortable compliance window - it has: Time for news - Time to try organic compliance - No immediate regulatory pressure. Statistically: Most companies do not announce RS at this stage - you can stay in the stock without immediate technical concerns.
.
🔹 Step 2: March 2026 (Start of pressure)
This is where the psychological change begins: Nasdaq is already expecting the plan - Management knows: If there is no $1 soon → RS is due - this is the stage where the market begins to “price in RS risk”. Sometimes you see: media silence - or the opposite - a “good” announcement in a last-ditch attempt - you can still stay - but with daily vigilance
.
🔹 Step 3: The critical risk point ⚠️
📅 Area March 25 – April 5, 2026

This is the most important area:
For RS to take effect before April 20, the company needs to decide and announce - giving 5 business days to allow for an effective day + trading days. In practice, this means: the RS announcement must be issued no later than early April.
Everyone invested in this company here, if you are still inside after the beginning of April - you are already inside the “RS window”. *Everything we wrote here - all investors know* - so it seems that the risk area is already towards the end of March.
Good luck to everyone.

[Trade Mind @OndStockMind]

$IXHL

A stock doesn't always go down after a reverse split - sometimes it goes up. A stock that has a lot of shorts on it, in fact the reverse split is their nightmare! Why are they scared of it? To make the stock go down!

Before RS: Shorters like $0.40 stocks

After RS: Fewer stocks, high risk, wide spread.

📌 So what do they do?
➡️ Close a short
➡️ Close = Buy
➡️ Buy = Green candle

A good example is the AREB stock that went up immediately on the announcement of a reverse split

[Trade Mind @OndStockMind]

$IXHL -

The text reviews a call from experts in the clinical research industry to abandon outdated approaches by 2026 in favor of more flexible and accurate scientific models. The researchers emphasize the need to move from symptom management to treating the root causes of diseases, using personalized medicine and advanced biomarkers. The article criticizes the reliance on rigid, isolated trials, and suggests instead designing adaptive trials that take into account the biological complexity and diversity of patients. In addition, the importance of including the patient voice early on is emphasized to ensure that the results are clinically meaningful and restore quality of life. In conclusion, the sources call for embracing learning from failures and selecting more relevant study populations to accelerate effective and safe drug development.

https://t.co/ZZxt3ACHWL